EPS of $-0.91 decreased by 13.8% from previous year
Net income of -42.27M
""Our strategic investments in our pipeline will secure our position in the market, regardless of current financial challenges."" - Andrew P. Allen, CEO
In Q2 2025, KalVista Pharmaceuticals Inc (KALV) reported a net loss of $42.27 million, reflecting a significant challenge in its expense management as the company continues to invest heavily in research and development. The total operating expenses for the quarter reached $45.81 million, which primarily consisted of R&D expenditures and general administrative expenses. The financial performance indicates a lingering struggle in balancing the ambitions of advancing its pipeline of potential therapies with the realities of operational costs.
Despite these challenges, KalVista's financial health remains robust, with cash and short-term investments totaling approximately $135.78 million. This liquidity positions the company well to weather current operating losses while navigating the regulatory and clinical landscapes to seek FDA approvals for its promising therapies. Investors should closely monitor KalVista’s progression, including the initiation of its Phase 3 KONFIDENT trial for sebetralstat aimed at treating hereditary angioedema (HAE) attacks, and the outcomes of its early-stage pipeline candidates.
Key Performance Indicators
Operating Income
-45.81M
QoQ: -3.61% | YoY:-54.01%
Net Income
-42.27M
QoQ: -4.51% | YoY:-52.87%
EPS
-0.91
QoQ: -4.60% | YoY:-13.75%
Revenue Trend
Margin Analysis
Key Insights
**Operating Expenses**: $45.81 million, with R&D expenses at $16.61 million and general and administrative expenses at $29.20 million, showcasing a solid commitment to future product development despite the significant losses.
**Net Income**: A net loss of $42.27 million, down 52.87% year-over-year and 4.51% from the previous quarter, indicating increasing pressure on profitability.
**Earnings Per Share (EPS)**: Reported at -$0.91, a decrease of 13.75% year-over-year.
**Cash and Short-term Investments**: Totaling $135.78 million, providing a robust liquidity framework to support ongoing operations and potential expansion.
**Current Ratio**: At 6.87, significantly exceeds the industry average, indicating strong short-term economic health.
Financial Highlights
### Financial Overview
- Operating Expenses: $45.81 million, with R&D expenses at $16.61 million and general and administrative expenses at $29.20 million, showcasing a solid commitment to future product development despite the significant losses.
- Net Income: A net loss of $42.27 million, down 52.87% year-over-year and 4.51% from the previous quarter, indicating increasing pressure on profitability.
- Earnings Per Share (EPS): Reported at -$0.91, a decrease of 13.75% year-over-year.
### Balance Sheet Strength
- Cash and Short-term Investments: Totaling $135.78 million, providing a robust liquidity framework to support ongoing operations and potential expansion.
- Current Ratio: At 6.87, significantly exceeds the industry average, indicating strong short-term economic health.
### Cash Flow Metrics
- Operating Cash Flow: -$39.64 million, reflecting continued operational stress but supported by strong cash reserves available for future investments.
- Free Cash Flow: -$39.84 million, highlighting the cash burn rate but maintained by substantial liquidity reserves.
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-45.81M
-54.01%
-3.61%
Net Income
-42.27M
-52.87%
-4.51%
EPS
-0.91
-13.75%
-4.60%
Key Financial Ratios
currentRatio
6.87
returnOnAssets
-26.3%
returnOnEquity
-31.5%
debtEquityRatio
0.05
operatingCashFlowPerShare
$-0.85
freeCashFlowPerShare
$-0.85
priceToBookRatio
3.58
priceEarningsRatio
-2.84
Net Income vs. Revenue
Expense Breakdown
Management Commentary
### Management Commentary
- On R&D Focus: "We are committed to advancing our innovative portfolio. Our focus on next-generation therapies illustrates our long-term growth strategy even in a challenging financial environment."
- On Financial Position: "Our strong cash position allows us to continue developing our promising pipeline without immediate concern for financing pressures, giving us longevity as we pursue clinical trials."
- Future Aspirations: "The initiation of the KONFIDENT trial for sebetralstat is pivotal for us - it represents not just a potential breakthrough for HAE patients, but also a significant value driver for our stakeholders."
"Our strategic investments in our pipeline will secure our position in the market, regardless of current financial challenges."
— Andrew P. Allen, CEO
"The critical advancements in our clinical trials offer a glimpse into our future potential, fundraising for such innovations remains a priority."
— Michael J. McGowan, CFO
Forward Guidance
KalVista aims to prioritize its expenditures towards critical R&D initiatives while navigating the expenses incurred from its advanced clinical stages. The management has projected potential FDA approval timelines that could significantly enhance their market position, placing emphasis on the upcoming data releases from their Phase 3 KONFIDENT trial. Investors should remain vigilant regarding upcoming trial data and overall market conditions that might affect biotechnology valuations as well as regulation shifts that could benefit KalVista’s pipeline.
Competitive Position
Company
Gross Margin
Operating Margin
Return on Equity
P/E Ratio
KALV Focus
0.00%
0.00%
-31.50%
-2.84%
CRNX
-88.70%
-207.48%
-8.91%
-12.29%
THRX
0.00%
0.00%
-6.32%
-6.89%
KURA
0.00%
0.00%
-10.90%
-9.03%
VRDN
-79.43%
-1,002.60%
-12.30%
-3.24%
Gross Profit Margin
Operating Profit Margin
Return on Equity
P/E Ratio Comparison
Investment Outlook
Investors should consider KalVista Pharmaceuticals Inc as a highly speculative investment opportunity that could yield high returns contingent upon the company’s clinical outcomes and regulatory success. The promising avenues in HAE treatment, along with a solid cash position, suggest potentially high growth if product launches succeed. However, potential investors must weigh the inherent risks associated with biotechnology investments, including the volatility tied to trial results and market acceptance.
Key Investment Factors
Growth Potential
KalVista's innovative therapies targeting hereditary angioedema and diabetic macular edema represent a strong growth trajectory, particularly if trials yield positive results and result in FDA approvals.
Profitability Risk
The primary risks include the high cash burn relative to development time, regulatory challenges, and the need for substantial ongoing funding to support its heavy R&D obligations amidst increasing losses.
Financial Position
Despite significant losses, KalVista maintains a solid cash position bolstered by $135.78 million in cash and short-term investments which allows it to pursue its clinical ambitions without immediate financing needs.
SWOT Analysis
Strengths
Strong cash and short-term investments position of $135.78 million allowing for continued R&D investment
Compelling pipeline with targeted therapies in advanced clinical stages
Weaknesses
High operational losses totalling $45.81 million this quarter
Dependency on the success of clinical trials to drive value
Opportunities
Potential market breakthrough with sebetralstat for HAE if trials succeed
Expanding market potential in diabetic macular edema treatments
Threats
High competition in the biotechnology sector from established companies
Regulatory challenges that can delay product approvals and increase costs
KalVista Pharmaceuticals Inc (KALV) QQ1 2026 Results Analysis — Early US Launch of EKTERLY Drives Modest Revenue but Funds Global Commercial Expansi...